Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 2/20 | 0.69 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455773 | 0.81 | FASN (1.00) | FASN | |
| SCHEMBL4468057 | 0.80 | FASN (0.95) | FASN | |
| SCHEMBL4456324 | 0.79 | FASN (0.78) | FASNGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4459606 | 0.78 | FASN (0.87) | FASN | |
| SCHEMBL4465168 | 0.77 | FASN (0.68) | FASNGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4466077 | 0.77 | FASN (0.78) | FASNGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8153358 | 0.77 | FASN (0.78) | FASNGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4466056 | 0.76 | FASN (0.73) | FASNGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8146955 | 0.76 | FASN (0.73) | FASN | |
| SCHEMBL4459413 | 0.75 | FASN (0.64) | FASNGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| WO-2007089634-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-0920319-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001070227-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6162813-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-6150522-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0918522-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 1999-08-18 | — | — | EP | disclosed |
| EP-0920319-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0918522-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997044037-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997044041-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | FASN, FADS2, FADS1 | FASN 1/4885GRIN2D 4366/4885GRIN3B 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.